Arrhythmias & electrophysiology
Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors
Authors' conclusion
TARFACT is a novel palliative treatment option for cardiac tumors, reducing accessible tumors and improving clinical symptoms in a preliminary group of patients.
Study context
- Population
- Patients with cardiac tumors (mucinous liposarcoma, myocardial hypertrophy with inflammatory cell infiltration mass, fibrous tissue tumor hyperplasia, myocardial clear cell sarcoma, cardiac rhabdomyoma)
- Participants
- 5 patients
- Exposure
- Tumor size, symptoms and cardiac function before vs after transapical radiofrequency ablation for cardiac tumors (TARFACT)
- TARFACTn = 5
- Outcome
- Safety and efficacy of TARFACT
Methodological detailsechocardiography-guided, transapical
- Echocardiography-guided
- Transapical
Main finding
As reported in the abstract
Tumor size · median follow-up 9 (range 4-12) months
| Group | Value | Width (mean ± SD) |
|---|---|---|
| Before TARFACT | mean 6.7 (SD 2.0) cm | 5.0 ± 2.1 cm |
| After TARFACT | mean 4.7 (SD 1.8) cm | 2.5 ± 0.7 cm |
Value
Before TARFACTmean 6.7 (SD 2.0) cm
After TARFACTmean 4.7 (SD 1.8) cm
Width (mean ± SD)
Before TARFACT5.0 ± 2.1 cm
After TARFACT2.5 ± 0.7 cm
- After TARFACT vs Before TARFACT: P = 0.007 — length
- After TARFACT vs Before TARFACT: P = 0.041 — width
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Echocardiography-Guided Radiofrequency Ablation for Cardiac Tumors. JACC CardioOncol. Published 30 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →